The results showed that colorectal cancer patients with high levels of MTA1 expression tended to be enriched with lower immunomodulation enrichment scores, which reflects an immunosuppressive status in their tumor tissues (Figure 1D). This evidence concerns the gene MTA1 and colorectal cancer.